Brief: Adial Pharmaceuticals Granted A 180 Calendar Day Extension By Nasdaq To Regain Compliance With The Minimum Bid Price Rule
03/09/2025 14:00
Sept 3 (Reuters) - Adial Pharmaceuticals Inc ADIL.O: ADIAL PHARMACEUTICALS GRANTED A 180 CALENDAR DAY EXTENSION BY NASDAQ TO REGAIN COMPLIANCE WITH THE MINIMUM BID PRICE RULE Source text: ID:nGNXb9WlRv Further company coverage: ADIL.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Adial Pharmaceuticals
See all newsBrief: Adial Pharmaceuticals Announces Name Change To Azora Therapeutics
Brief: Adial Pharmaceuticals Announces Planned Appointment Of Celia Economides As Chief Financial Officer
Brief: Adial Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Brief: Adial Pharmaceuticals - Proposed Resale Of Up To 25,148,970 Shares Of Common Stock By Selling Stockholders - SEC Filing
Brief: Adial Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)